- Trial phase
- Phase 3 (completed)
- Time to market
- Otsuka has not yet announced a formal regulatory submission. If filed under an expedited pathway (breakthrough therapy or priority review), FDA action could come 6-10 months after submission, potentially in late 2027 or early 2028.
- Why 4/10
- The Phase 3 topline readout (the most recent hard catalyst) occurred on September 22, 2026 and was positive. No formal regulatory submission or PDUFA date has been announced as of November 10, 2026. Without a dated binary catalyst in the next ~12 months, the impact score is capped at 4. Ulefnersen is also a partnered asset (Otsuka leads regulatory), reducing its concentration as a value driver for Ionis.
The Phase 3 binary is past (positive, September 2026). The next catalyst is Otsuka's regulatory submission to the FDA, which Otsuka said it would pursue with urgency but no formal filing or PDUFA date has been announced as of November 10, 2026. Watch for Otsuka to announce an NDA/BLA submission and potential priority review or breakthrough therapy designation. For Ionis, ulefnersen is a partnered royalty asset; the stock's near-term direction is more driven by Tryngolza commercial execution.
Price Chart
Executive Summary
Ulefnersen is an investigational antisense oligonucleotide (RNA-targeted medicine) for FUS-ALS, a rare genetic form of ALS caused by mutations in the FUS gene. In September 2026, the Phase 3 FUSION trial met its primary endpoint with high statistical significance (p=0.0005), showing improved function and survival versus placebo. Otsuka Pharmaceutical, which licensed the drug from Ionis in 2024, plans to discuss expedited submission pathways with the FDA and has launched an Early Access Program. For Ionis, ulefnersen represents a milestone-and-royalty asset with no commercial expense, but the stock's near-term performance has been dominated by Tryngolza commercial struggles, which drove a 21% single-day drop on November 9, 2026.
How It Works
Ulefnersen is an antisense oligonucleotide (ASO), a type of synthetic genetic medicine designed to target and degrade the faulty messenger RNA produced by mutations in the FUS gene. By reducing production of the toxic FUS protein, it aims to slow or halt the nerve-cell death that causes ALS in patients with this specific genetic form of the disease. It is administered via intrathecal injection (into the spinal fluid) to reach the central nervous system.
Trial Status
The Phase 3 FUSION trial (intrathecal ulefnersen vs placebo in FUS-ALS patients) met its primary endpoint in September 2026, demonstrating statistically significant improvement on a joint rank analysis of function (ALSFRS-R score) and survival (time to death or permanent ventilation) with p=0.0005. Secondary endpoints including serum neurofilament light chain (NfL) also showed statistically significant improvement. Otsuka is conducting further prespecified and exploratory analyses.
The Two-Sided Case
Upcoming Catalysts
- Otsuka's formal NDA/BLA submission to the FDA (date not yet announced)
- Potential FDA breakthrough therapy or priority review designation
- Regulatory decisions in other global markets (EU, Japan) if Otsuka files simultaneously
- Presentation of full Phase 3 FUSION data at a medical conference
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IONIS PHARMACEUTICALS INC 8-K IONS ·Originating report